Research Article|Articles in Press

Building a CAT Clinic - real-world systems approaches to prevention and treatment


      • Cancer associated thrombosis is a common complication among patients with active malignancy.
      • Cancer associated thrombosis (CAT) clinics can improve patient outcomes by targeting patients at high risk of VTE.
      • CAT clinics can provide standardized outpatient care for acute VTE management in the majority of ambulatory cancer patients.
      • CAT clinics can provide education to patients and can aid in implementing current guideline recommendations for primary VTE prophylaxis


      Cancer patients have an increased risk of developing venous thrombosis. The implementation of a cancer associated thrombosis clinic can be instrumental for the prevention, early recognition, and management of venous thromboembolism in this vulnerable population. Cancer thrombosis clinics rely on a multidisciplinary approach to care and require standardization along with a dedicated team of healthcare professionals. Cancer thrombosis clinics have the potential to improve patient outcomes and lower healthcare expenditure. Herein, we describe a successful model of a cancer thrombosis clinic and highlight the potential impact on clinical outcomes.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Heit J.A.
        • Spencer F.A.
        • White R.H.
        The epidemiology of venous thromboembolism.
        J. Thromb. Thrombolysis. 2016; 41: 3-14
        • Heit J.A.
        • Silverstein M.D.
        • Mohr D.N.
        • Petterson T.M.
        • O'Fallon W.M.
        • Melton 3rd., L.J.
        Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.
        Arch. Intern. Med. 2000; 160: 809-815
        • Khorana A.A.
        • Francis C.W.
        • Culakova E.
        • Kuderer N.M.
        • Lyman G.H.
        Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.
        J. Thromb. Haemost. 2007; 5: 632-634
        • Khorana A.A.
        • Dalal M.R.
        • Lin J.
        • Connolly G.C.
        Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States.
        Clinicoecon Outcomes Res. 2013; 5: 101-108
        • Fernandez M.M.
        • Hogue S.
        • Preblick R.
        • Kwong W.J.
        Review of the cost of venous thromboembolism.
        ClinicoEconomics and outcomes research : CEOR. 2015; 7: 451-462
        • Rabinovich E.
        • Bartholomew J.R.
        • Wilks M.L.
        • Tripp B.L.
        • McCrae K.R.
        • Khorana A.A.
        Centralizing care of cancer-associated thromboembolism: the Cleveland Clinic experience.
        Thromb. Res. 2016; 147: 102-103
      1. TEN CATE-HOEK AJ, TOLL DB, BÜLLER HR, HOES AW, MOONS KGM, OUDEGA R, et al. Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual. J. Thromb. Haemost. 2009;7(12):2042–9.

        • Wiener R.S.
        • Gould M.K.
        • Arenberg D.A.
        • Au D.H.
        • Fennig K.
        • Lamb C.R.
        • et al.
        An official American Thoracic Society/American College of Chest Physicians Policy Statement: implementation of low-dose computed tomography lung Cancer screening programs in clinical practice.
        Am. J. Respir. Crit. Care Med. 2015; 192: 881-891
        • Raja A.S.
        • Greenberg J.O.
        • Qaseem A.
        • Denberg T.D.
        • Fitterman N.
        • Schuur J.D.
        Evaluation of patients with suspected acute pulmonary embolism: best practice advice from the clinical guidelines Committee of the American College of physicians.
        Ann. Intern. Med. 2015; 163: 701-711
      2. Qdaisat A, Yeung S-cJ, Variyam DE, Badugu P, Ghaly F, Rice TW, et al. Evaluation of Cancer Patients With Suspected Pulmonary Embolism: Performance of the American College of Physicians Guideline. Journal of the American College of Radiology. 2020;17(1, Part A):22–30.

        • Aujesky D.
        • Roy P.M.
        • Verschuren F.
        • Righini M.
        • Osterwalder J.
        • Egloff M.
        • et al.
        Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
        Lancet (London, England). 2011; 378: 41-48
        • Beam D.M.
        • Kahler Z.P.
        • Kline J.A.
        Immediate discharge and home treatment with rivaroxaban of low-risk venous thromboembolism diagnosed in two U.S. emergency departments: a one-year preplanned analysis.
        Acad. Emerg. Med. 2015; 22: 788-795
        • Donzé J.
        • Le Gal G.
        • Fine M.J.
        • Roy P.M.
        • Sanchez O.
        • Verschuren F.
        • et al.
        Prospective validation of the pulmonary embolism severity index. A clinical prognostic model for pulmonary embolism.
        Thromb. Haemost. 2008; 100: 943-948
        • Jiménez D.
        • Aujesky D.
        • Moores L.
        • Gómez V.
        • Lobo J.L.
        • Uresandi F.
        • et al.
        Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism.
        Arch. Intern. Med. 2010; 170: 1383-1389
        • Kline J.A.
        • Roy P.M.
        • Than M.P.
        • Hernandez J.
        • Courtney D.M.
        • Jones A.E.
        • et al.
        Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: the POMPE-C tool.
        Thromb. Res. 2012; 129: e194-e199
        • Khorana A.A.
        • Kuderer N.M.
        • Culakova E.
        • Lyman G.H.
        • Francis C.W.
        Development and validation of a predictive model for chemotherapy-associated thrombosis.
        Blood. 2008; 111: 4902-4907
      3. Lyman GH, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with Cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Oncology Practice. 2015;11(3):e442-e4.

        • Kunapareddy G.
        • Switzer B.
        • Jain P.
        • Conces M.
        • Chen Y.-W.
        • Patel B.
        • et al.
        Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting.
        Research and Practice in Thrombosis and Haemostasis. 2019; 3: 226-233
        • Poudel S.K.
        • Park D.Y.
        • Jia X.
        • Wilks M.
        • Pinkava V.
        • O'Brien M.
        • et al.
        Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: the Cleveland Clinic experience.
        J. Thromb. Haemost. 2020; 18: 651-659
        • Angelini D.
        • Attia D.
        • Wei W.
        • Wilks M.
        • Tripp B.
        • D'Andrea C.
        • et al.
        Bleeding outcomes of gastrointestinal Cancer patients treated with direct Oral anticoagulants vs. low molecular weight heparin.
        Blood. 2020; 136: 27
        • Attia D.
        • Jia X.
        • Wilks M.
        • Tripp B.
        • D'Andrea C.
        • McCrae K.
        • et al.
        Risk of recurrent venous thromboembolism and bleeding in patients with Cancer associated thrombosis.
        Blood. 2020; 136: 18
        • Poudel S.K.
        • Reddy C.A.
        • Park D.Y.
        • Wilks M.L.
        • Pinkava V.
        • O'Brien M.
        • et al.
        Clinical outcomes of Cancer-associated thrombosis beyond 6 months of anticoagulation.
        Blood. 2019; 134: 3458
        • Soff G.A.
        • Mones J.
        • Wilkins C.
        • Devlin S.
        • Haegler-Laube E.
        • Wills J.
        • et al.
        Rivaroxaban treatment of cancer-associated venous thromboembolism: memorial Sloan Kettering Cancer center institutional experience.
        Res Pract Thromb Haemost. 2019; 3: 349-356
        • Bott-Kitslaar D.M.
        • Saadiq R.A.
        • McBane R.D.
        • Loprinzi C.L.
        • Ashrani A.A.
        • Ransone T.R.
        • et al.
        Efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy: a single-center registry.
        Am. J. Med. 2016; 129: 615-619
        • Wysokinski W.E.
        • Houghton D.E.
        • Casanegra A.I.
        • Vlazny D.T.
        • Bott-Kitslaar D.M.
        • Froehling D.A.
        • et al.
        Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
        Am. J. Hematol. 2019; 94: 1185-1192
        • Laube E.S.
        • Mantha S.
        • Samedy P.
        • Wills J.
        • Harnicar S.
        • Soff G.A.
        Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban.
        Am. J. Hematol. 2017; 92: E9-E10
        • Carrier M.
        • Abou-Nassar K.
        • Mallick R.
        • Tagalakis V.
        • Shivakumar S.
        • Schattner A.
        • et al.
        Apixaban to prevent venous thromboembolism in patients with Cancer.
        N. Engl. J. Med. 2019; 380: 711-719
        • Khorana A.A.
        • Soff G.A.
        • Kakkar A.K.
        • Vadhan-Raj S.
        • Riess H.
        • Wun T.
        • et al.
        Rivaroxaban for Thromboprophylaxis in high-risk ambulatory patients with Cancer.
        N. Engl. J. Med. 2019; 380: 720-728
        • Bosch F.T.M.
        • Mulder F.I.
        • Kamphuisen P.W.
        • Middeldorp S.
        • Bossuyt P.M.
        • Büller H.R.
        • et al.
        Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis.
        Blood advances. 2020; 4: 5215-5225
        • Wang T.F.
        • Zwicker J.I.
        • Ay C.
        • Pabinger I.
        • Falanga A.
        • Antic D.
        • et al.
        The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH.
        J. Thromb. Haemost. 2019; 17: 1772-1778
        • Key N.S.
        • Khorana A.A.
        • Kuderer N.M.
        • Bohlke K.
        • Lee A.Y.Y.
        • Arcelus J.I.
        • et al.
        Venous thromboembolism prophylaxis and treatment in patients with Cancer: ASCO clinical practice guideline update.
        J. Clin. Oncol. 2020; 38: 496-520
      4. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. The Lancet Oncology. 2019;20(10):e566-e81.

      5. Holmes CE, Ades S, Gilchrist S, Douce D, Libby K, Rogala B, et al. Successful model for guideline implementation to prevent Cancer-associated thrombosis: venous thromboembolism prevention in the ambulatory Cancer clinic. JCO Oncology Practice. 2020;16(9):e868-e74.

        • Verso M.
        • Agnelli G.
        • Barni S.
        • Gasparini G.
        • LaBianca R.
        A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.
        Intern. Emerg. Med. 2012; 7: 291-292
        • Mulder F.I.
        • Horváth-Puhó E.
        • van Es N.
        • van Laarhoven H.W.M.
        • Pedersen L.
        • Moik F.
        • et al.
        Venous thromboembolism in cancer patients: a population-based cohort study.
        Blood. 2021; 137: 1959-1969
        • Roopkumar J.
        • Swaidani S.
        • Kim A.S.
        • Thapa B.
        • Gervaso L.
        • Hobbs B.P.
        • et al.
        Increased incidence of venous thromboembolism with Cancer immunotherapy.
        Med (N Y). 2021; 2: 423-434

      Linked Article

      • Publisher note
        Thrombosis ResearchVol. 208
        • Preview
          Building a CAT clinic - real-world systems approaches to prevention and treatment” by Dana E.Angelini Alok A.Khorana is intended for publication in the ICTHIC - International Conference on Thrombosis and Hemostasis Issues in Cancer supplement and not part of the Thrombosis Research regular journal issue. As the article was included in the issue incorrectly. We will correct the error and replace the article for inclusion in the supplement issue. The Publisher apologizes for any inconvenience this may cause.
        • Full-Text
        • PDF